The aff causes political uncertainty and revenue decline for pharma companies---that causes them to cut new RnD programs
David Epstein 17, executive partner at Flagship Pioneering. March 17. “The next horizon of innovation for pharma” http://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/the-next-horizon-of-innovation-for-pharma
You also have to look at the external environment and think about what could go wrong. We should always worry when there’s political change. For instance, when payors—which is the government in most parts of the world—come under economic pressure, changes in legislation could disrupt the innovation process. If all of a sudden investors had no hope of being able to take their companies public and make a good return, that money would dry up, as would innovation. If pharma companies saw prices fall so far that their margins came under huge pressure, they would cut costs and reduce R&D as well as other spending. Eventually there would be an industry shakeout, and it would correct itself, but you’d have several years or longer where things slowed down or paused, and that’s an ongoing risk.